NR4A3 and triple-negative breast carcinoma: Therapeutically, breast AciCCs are managed according to triple-negative breast cancer protocols, while salivary gland AciCCs may benefit from emerging targeted approaches based on NR4A3-driven oncogenesis [89,98,99,101,103,104].